Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Yet oncology products have a greater likelihood than other therapy areas to fail at Phase III (see graph) – well after the branding process has already begun and market expectations are somewhat ...

Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...

Joe DePinto, MBA, discussed the findings of the McKesson 2024 Cell and Gene Therapy Report, providing insight into the ...

Early in 2024, we reported on the FDA's call for new boxed warnings on the labeling of all approved chimeric antigen receptor ...

The latest advances in cancer therapy, coupled with the drive to bring new drugs to market via accelerated access programmes, means market researchers must keep pace to support optimum positioning.

Wall Street did not react favorably to the plan. Windtree stock dropped to a new low of 25 cents per share Wednesday morning ...

We recently compiled a list of the 12 Best Penny Stocks to Invest in According to the Media. In this article, we are going to ...

REGIONS NEWS Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos ...

Top stocks for 2025 are from the companies that have proven growth track records and strong outlooks, with more potential ...